ImmunityBio (IBRX) shares jumped 19.12 percent to $10.36, up $1.66 on Monday, after the company reported sharply higher fourth-quarter and full-year revenue driven by strong product sales growth.
The stock is currently trading at $10.82, compared with a previous close of $8.70 on the Nasdaq. It opened at $9.93 and has traded between $9.74 and $11.00 during the session. Trading volume stands at 24.33 million shares, compared with its average volume of 30.23 million shares.
For the fourth quarter, total revenue surged to $38.3 million from $7.6 million a year earlier, as product revenue climbed to $38.3 million from $7.2 million. Net loss was $61.9 million, or $0.06 per share, compared with $59.2 million, or $0.08 and $0.09 per share, respectively, in the prior-year period. For the full year, revenue rose to $113.3 million from $14.7 million, while net loss narrowed to $351.4 million from $413.6 million.
The stock has traded in a 52-week range of $1.83 to $11.00.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.